Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age18+
SponsorWomen's Hospital School Of Medicine Zhejiang University
About this trial
Efficacy evaluate of iparomlimab and tuvonralimab (a PD-1/CTLA-4 bispecific antibody) in patients with surgically resectable dMMR endometrial cancer.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age:18 years or older.
Histologically confirmed endometrial cancer (excluding carcinosarcoma).
FIGO (2009) stage I to IIIC2 disease that is considered surgically completely resectable.
Must agree to use contraception from the time of informed consent until at least 5 months after the last dose of the investigational product.
Disqualifiers
Myocardial infarction;
Unstable angina pectoris;
Congestive heart failure of New York Heart Association (NYHA) Class III or IV
Poorly controlled hypertension despite appropriate treatment (e.g., sustained systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥90 mmHg for ≥ 24 hours)
Trial design
Design model
Single group
Treatments tested in this trial
Iparomlimab and Tuvonralimab (QL1706)
DrugIparomlimab and Tuvonralimab as a strategy to facilitate non-surgical management in women with surgically completely resectable dMMR endometrial cancer.
Treatment groups
30 Participants
are divided into 1 treatment groupGroup A: ImmunotherapyExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Pathological or clinical complete response rate
Time frame
From the time of enrollment until 12 months after the completion of treatmentLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: